• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Jay Feldstein, DO, Corporate Chief Medical Officer, The AmeriHealth Mercy Family of Companies


As a Medicaid plan, AmeriHealth Mercy needs innovative approaches to treat its unique population.

Jay Feldstein, DO
Corporate Chief Medical Officer
The AmeriHealth Mercy Family of Companies
Philadelphia, Penn.

"Our efforts have made a positive impact on clinical outcomes for those we touch and have enhanced patient/physician relationships," says Dr. Feldstein.

Prior to joining AmeriHealth Mercy, Dr. Feldstein served as senior medical director for Aetna's Mid-Atlantic Region, for which he was responsible for creating and implementing medical cost and quality initiatives and developing provider relations and communications strategies.

He received a B.A. degree from Penn State University and his D.O. degree from the Philadelphia College of Osteopathic Medicine. He is a fellow of the American College of Preventive Medicine.

Related Content
© 2024 MJH Life Sciences

All rights reserved.